Epinephrine Syringes Deemed Safe for Continued Sale
Published Date: 6/2/2025
Notice
Summary
The FDA says epinephrine prefilled syringes for IV use weren’t pulled from the market because of safety or effectiveness problems. This means drug makers can keep getting approval to sell similar versions, so patients and healthcare providers won’t face shortages. No changes in cost or timing are expected, just smooth sailing ahead for this important medicine.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Epinephrine IV Syringe Remains Approved
The FDA determined that EPINEPHRINE (epinephrine) solution, 1 mg/mL, prefilled syringe for intravenous use was not withdrawn from sale for reasons of safety or effectiveness. Because of that, the FDA will not start procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to this product, which helps keep patient access stable.
Generic Applicants Can Keep Seeking Approval
The FDA said it will continue to approve ANDAs that refer to EPINEPHRINE 1 mg/mL prefilled syringe for IV use as long as applicants meet legal and regulatory requirements. That means drug makers can keep applying for approval of generic versions that rely on this product.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-09900, M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help drug makers skip extra tests for different pill strengths if one strength already proved it works. This means faster approvals and less hassle for companies making immediate-release tablets and capsules. If you’re in the drug biz, keep an eye out—this could save time and money starting late 2024!
Next: 2025-09902, Performance Review Board Membership
The Merit Systems Protection Board just named the new members of its Senior Executive Service Performance Review Board, replacing all past member lists. This update affects senior federal employees who get reviewed for their job performance. No changes to pay or timing are mentioned, but it keeps the review process fresh and official.